Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triamcinolone + gatifloxacin is a fixed-dose combination of two active pharmaceutical ingredients used primarily in ophthalmology. Triamcinolone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, acting by inhibiting multiple inflammatory cytokines and suppressing the immune response. Gatifloxacin is a fourth-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. The combination is typically formulated as an ophthalmic preparation (eye drops or injections) to treat or prevent ocular inflammation (from triamcinolone) and bacterial infections (from gatifloxacin), especially after eye surgery or in severe ocular inflammatory conditions at risk of secondary infection[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone + gatifloxacin.